Inclusion and Exclusion Criteria:

          -  Patients must be newly diagnosed with localized primary CNS non germinomatous germ
             cell tumor (NGGCT) (Stratum 1) or localized primary CNS germinoma (Stratum 2); germ
             cell tumors (GCTs) located in the suprasellar, pineal, bifocal (pineal +suprasellar),
             and ventricles are eligible; tumors present in the above mentioned locations and with
             unifocal parenchymal extension are eligible

               -  Stratum 1( NGGCT): Patients must have one of the following criteria:

                    -  Patients with serum and/or CSF hCGβ > 100 mIU/mL or any elevation of serum
                       and CSF alpha-fetoprotein (AFP) > 10 ng/mL or greater than the institutional
                       normal are eligible, irrespective of biopsy results

                    -  Patients with any of the following elements on biopsy/resection are
                       eligible, irrespective of serum and/or CSF hCGβ and AFP levels: endodermal
                       sinus tumor (yolk sac),embryonal carcinoma, choriocarcinoma,
                       malignant/immature teratoma, and mixed GCT with malignant GCT elements

               -  Stratum 2 (Germinoma): Patients must have one of the following criteria:

                    -  Patients with institutional normal AFP AND hCGβ 5 to ≤ 50 mIU/mL in serum
                       and/or CSF are eligible; no histologic confirmation required

                    -  Patients with bifocal (pineal + suprasellar) involvement or pineal lesion
                       with diabetes insipidus AND hCGβ ≤ 100 mIU/mL and institutional normal AFP
                       in serum and/or CSF are eligible; no histologic confirmation required

                    -  Patients with histologically confirmed germinoma or germinoma mixed with
                       mature teratoma and hCGβ ≤ 100 mIU/mL and institutional normal AFP in serum
                       and/or CSF are eligible

          -  Patients must have negative lumbar CSF cytology; lumbar CSF must be obtained unless
             medically contraindicated

          -  Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1123

          -  Patients with mature teratoma with normal tumor markers are not eligible

          -  Patients with tumors located outside the ventricles (basal ganglia, thalamus) are not
             eligible

          -  Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are
             not eligible

          -  Peripheral absolute neutrophil count (ANC) ≥ 1,000/μL

          -  Platelet count ≥ 100,000/μL (transfusion independent)

          -  Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions)

          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² OR serum creatinine based
             on age/gender as follows:

               -  0.4 mg/dL ( 1 month to < 6 months of age)

               -  0.5 mg/dL (6 months to < 1 year of age)

               -  0.6 mg/dL (1 to < 2 years of age)

               -  0.8 mg/dL (2 to < 6 years of age)

               -  1.0 mg/dL (6 to < 10 years of age)

               -  1.2 mg/dL (10 to < 13 years of age)

               -  1.5 mg/dL (male) and 1.4 mg/dL (female) (13 to < 16 years of age)

               -  1.7 mg/dL (male) and 1.4 mg/dL (female) (≥ 16 years of age)

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamic pyruvate transaminase(SGPT) (alanine aminotransferase [ALT]) < 2.5
             times ULN

          -  Patients with seizure disorder may be enrolled if well controlled

          -  Patients must not be in status, coma, or assisted ventilation prior to study
             enrollment

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible unless they have agreed not to breastfeed their
             infants

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation

          -  Patients who had more than 1 prior surgery/biopsy are eligible

          -  Patients must not have received any prior tumor-directed therapy other than surgical
             intervention and corticosteroids.